HRP20000004A2 - (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders - Google Patents

(+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Info

Publication number: HRP20000004A2
Authority: HR; Croatia
Prior art keywords: norcisapride; useful; mediated disorders; intestinal disorders; treating gastro
Prior art date: 1997-07-11

Application number

HR20000004A

Other languages

English (en)

Inventor

Jozef Jan Pieter Heykants

Antonius Adrianus Hendr Megens

Willem Emiel Gusta Meuldermans

Joannes Adrianus Jac Schuurkes

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-11

Filing date

2000-01-05

Publication date

2000-12-31

2000-01-05 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2000-12-31 Publication of HRP20000004A2 publication Critical patent/HRP20000004A2/xx

Links

ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
238000007792 addition Methods 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Obesity (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Preparing Plates And Mask In Photomechanical Process (AREA)

HR20000004A 1997-07-11 2000-01-05 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders HRP20000004A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP97202161		1997-07-11
EP98200661		1998-03-04
PCT/EP1998/004193 WO1999002496A1 (en)	1997-07-11	1998-07-07	(+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Publications (1)

Publication Number	Publication Date
HRP20000004A2 true HRP20000004A2 (en)	2000-12-31

Family

ID=26146686

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20000004A HRP20000004A2 (en)	1997-07-11	2000-01-05	(+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Country Status (31)

Country	Link
US (2)	US20030060485A1 (de)
EP (1)	EP1000029B1 (de)
JP (1)	JP3529102B2 (de)
KR (1)	KR100358374B1 (de)
CN (1)	CN1196681C (de)
AT (1)	ATE251139T1 (de)
AU (1)	AU757077B2 (de)
BG (1)	BG64824B1 (de)
BR (1)	BR9811676A (de)
CA (1)	CA2292480A1 (de)
CO (1)	CO4940432A1 (de)
CZ (1)	CZ296212B6 (de)
DE (1)	DE69818678T2 (de)
DK (1)	DK1000029T3 (de)
EA (1)	EA002362B1 (de)
EE (1)	EE04491B1 (de)
ES (1)	ES2209190T3 (de)
HK (1)	HK1025092A1 (de)
HR (1)	HRP20000004A2 (de)
HU (1)	HUP0003078A3 (de)
ID (1)	ID24228A (de)
IL (1)	IL133225A (de)
MY (1)	MY129130A (de)
NO (1)	NO315183B1 (de)
NZ (1)	NZ502207A (de)
PL (1)	PL190296B1 (de)
PT (1)	PT1000029E (de)
SK (1)	SK284941B6 (de)
TR (1)	TR200000020T2 (de)
TW (1)	TW553934B (de)
WO (1)	WO1999002496A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147093A (en) *	1996-07-19	2000-11-14	Sepracor Inc.	Methods for treating gastroesophageal reflux disease
EP1468685A3 (de) *	1998-06-15	2004-12-15	Sepracor Inc.	Verwendung von optisch reines (+)-Norcisapride für die Behandlung von Apnea, Bulimia und andere Krankheiten
TR200103762T2 (tr)	1998-06-15	2002-05-21	Sepracor Inc.	Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı.
EP1464333A3 (de) *	1998-06-15	2004-12-15	Sepracor Inc.	Verwendung von optisch reines (-) Norcisapride in der Behandlung von Apnea, Bulimia und andere Krankheiten
CZ20004737A3 (cs)	1998-06-15	2001-10-17	Sepracor Inc.	Farmaceutický prostředek
US6362202B1 (en) *	1999-03-02	2002-03-26	Sepracor Inc.	Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) *	1999-03-02	2002-03-05	Sepracor, Inc.	Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2310166T3 (es) *	1999-08-03	2009-01-01	Lilly Icos Llc	Composicion farmaceutica que contiene tadalafil.
US6552046B2 (en) *	2000-06-07	2003-04-22	Aryx Therapeutics	Materials and methods for the treatment of gastroesophageal reflux disease
AU2002231627A1 (en) *	2000-11-24	2002-06-03	Janssen Pharmaceutica N.V.	Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
HUP0402611A2 (hu) *	2001-10-08	2005-07-28	Sun Pharmaceutical Industries Limited	Görcsoldó hatóanyag szakaszos leadására szolgáló rendszer
JP2003342186A (ja) *	2002-05-24	2003-12-03	Taisho Pharmaceut Co Ltd	鼻炎用内服液剤組成物
US8138204B2 (en)	2004-01-07	2012-03-20	Aryx Therapeutics, Inc.	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en)	2004-01-07	2013-09-03	Armetheon, Inc.	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2194053B1 (de)	2004-01-07	2013-03-27	Armetheon, Inc.	Methoxypiperidinderivate zur Ververwendung bei der Behandlung von Erkrankungen des Magen-Darm-Trakts und des zentralen Nervensystems
US20060247180A1 (en) *	2005-04-29	2006-11-02	Bergey James L	Purgative composition and uses thereof
EP1919909B1 (de)	2005-08-31	2013-08-21	Armetheon, Inc.	Synthetische verfahren und zwischenprodukte für stereoisomere verbindungen, die sich für die behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems eignen
KR20100026641A (ko) *	2008-09-01	2010-03-10	동아제약주식회사	신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
CN110913842A (zh) *	2017-07-19	2020-03-24	伊尼塔公司	包括恩曲替尼的药物组合物
JP2021530494A (ja) *	2018-07-11	2021-11-11	デューク・ユニヴァーシティ	胃腸障害の治療における徐放性５−ヒドロキシトリプトファンの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1183847A (en) *	1981-10-01	1985-03-12	Georges Van Daele	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4820715A (en) *	1984-06-28	1989-04-11	Bristol-Myers Company	Anti-emetic quinuclidinyl benzamides
NZ225152A (en) *	1987-07-17	1990-04-26	Janssen Pharmaceutica Nv	Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
US4975439A (en) *	1987-09-25	1990-12-04	Janssen Pharmaceutical N.V.	Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
IL89848A (en) *	1988-04-07	1997-08-14	Sepracor	Chiral ester derivatives
TW243449B (de) *	1991-02-15	1995-03-21	Hokuriku Pharmaceutical
TW294595B (de) *	1992-11-20	1997-01-01	Janssen Pharmaceutica Nv
FR2717174B1 (fr) *	1994-03-14	1996-05-31	Sanofi Sa	Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
US5712293A (en) *	1995-06-07	1998-01-27	Sepracor, Inc.	Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) *	1996-07-19	2000-11-14	Sepracor Inc.	Methods for treating gastroesophageal reflux disease
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

1998
- 1998-07-07 PL PL98337648A patent/PL190296B1/pl unknown
- 1998-07-07 BR BR9811676-2A patent/BR9811676A/pt not_active Application Discontinuation
- 1998-07-07 IL IL13322598A patent/IL133225A/xx not_active IP Right Cessation
- 1998-07-07 WO PCT/EP1998/004193 patent/WO1999002496A1/en active IP Right Grant
- 1998-07-07 DK DK98940159T patent/DK1000029T3/da active
- 1998-07-07 AU AU88575/98A patent/AU757077B2/en not_active Ceased
- 1998-07-07 EP EP98940159A patent/EP1000029B1/de not_active Expired - Lifetime
- 1998-07-07 CZ CZ0461799A patent/CZ296212B6/cs not_active IP Right Cessation
- 1998-07-07 PT PT98940159T patent/PT1000029E/pt unknown
- 1998-07-07 DE DE69818678T patent/DE69818678T2/de not_active Expired - Fee Related
- 1998-07-07 EE EEP200000014A patent/EE04491B1/xx not_active IP Right Cessation
- 1998-07-07 TR TR2000/00020T patent/TR200000020T2/xx unknown
- 1998-07-07 HU HU0003078A patent/HUP0003078A3/hu unknown
- 1998-07-07 ID IDW20000033A patent/ID24228A/id unknown
- 1998-07-07 ES ES98940159T patent/ES2209190T3/es not_active Expired - Lifetime
- 1998-07-07 SK SK1829-99A patent/SK284941B6/sk unknown
- 1998-07-07 AT AT98940159T patent/ATE251139T1/de not_active IP Right Cessation
- 1998-07-07 JP JP50812899A patent/JP3529102B2/ja not_active Expired - Fee Related
- 1998-07-07 NZ NZ502207A patent/NZ502207A/en unknown
- 1998-07-07 KR KR1019997012056A patent/KR100358374B1/ko not_active IP Right Cessation
- 1998-07-07 CA CA002292480A patent/CA2292480A1/en not_active Abandoned
- 1998-07-07 EA EA200000057A patent/EA002362B1/ru not_active IP Right Cessation
- 1998-07-07 CN CNB988069563A patent/CN1196681C/zh not_active Expired - Fee Related
- 1998-07-08 TW TW087111013A patent/TW553934B/zh not_active IP Right Cessation
- 1998-07-08 MY MYPI98003108A patent/MY129130A/en unknown
- 1998-07-09 CO CO98038980A patent/CO4940432A1/es unknown
1999
- 1999-11-30 BG BG103934A patent/BG64824B1/bg unknown
2000
- 2000-01-05 HR HR20000004A patent/HRP20000004A2/xx not_active Application Discontinuation
- 2000-01-07 NO NO20000093A patent/NO315183B1/no unknown
- 2000-07-08 HK HK00104200A patent/HK1025092A1/xx not_active IP Right Cessation
2002
- 2002-09-16 US US10/244,365 patent/US20030060485A1/en not_active Abandoned
2004
- 2004-03-23 US US10/807,035 patent/US20040176414A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ502207A (en)	2001-08-31
SK284941B6 (sk)	2006-02-02
EP1000029A1 (de)	2000-05-17
DE69818678D1 (de)	2003-11-06
PL190296B1 (pl)	2005-11-30
BR9811676A (pt)	2000-09-19
PT1000029E (pt)	2004-02-27
DK1000029T3 (da)	2004-02-23
TW553934B (en)	2003-09-21
US20030060485A1 (en)	2003-03-27
CZ461799A3 (cs)	2000-05-17
IL133225A0 (en)	2001-03-19
WO1999002496A1 (en)	1999-01-21
CZ296212B6 (cs)	2006-02-15
ID24228A (id)	2000-07-13
KR100358374B1 (ko)	2002-10-25
SK182999A3 (en)	2000-08-14
CA2292480A1 (en)	1999-01-21
HK1025092A1 (en)	2000-11-03
TR200000020T2 (tr)	2000-09-21
NO20000093D0 (no)	2000-01-07
EA200000057A1 (ru)	2000-08-28
NO20000093L (no)	2000-03-10
JP3529102B2 (ja)	2004-05-24
BG103934A (en)	2000-11-30
HUP0003078A3 (en)	2002-02-28
CN1196681C (zh)	2005-04-13
EE04491B1 (et)	2005-06-15
EE200000014A (et)	2000-10-16
US20040176414A1 (en)	2004-09-09
EA002362B1 (ru)	2002-04-25
CO4940432A1 (es)	2000-07-24
ES2209190T3 (es)	2004-06-16
HUP0003078A2 (hu)	2001-01-29
CN1262675A (zh)	2000-08-09
AU8857598A (en)	1999-02-08
MY129130A (en)	2007-03-30
NO315183B1 (no)	2003-07-28
EP1000029B1 (de)	2003-10-01
IL133225A (en)	2005-12-18
BG64824B1 (bg)	2006-05-31
DE69818678T2 (de)	2004-07-15
ATE251139T1 (de)	2003-10-15
AU757077B2 (en)	2003-01-30
PL337648A1 (en)	2000-08-28
JP2000515560A (ja)	2000-11-21
KR20010014027A (ko)	2001-02-26

Legal Events

Date	Code	Title	Description
2000-12-31	A1OB	Publication of a patent application
2001-06-25	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2007-07-05	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20070705 Year of fee payment: 10
2008-11-20	OBST	Application withdrawn

Publication	Publication Date	Title
HRP20000004A2 (en)	2000-12-31	(+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
MX9707980A (es)	1998-04-30	Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
BG102999A (en)	1999-09-30	New 2,3-diasubstituted-4-(3h)-quinazolinons
UA29476C2 (uk)	2000-11-15	Трансдермальна терапевтична система, що містить естрадіол
CA2272584A1 (en)	1998-06-04	Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
UA27749C2 (uk)	2000-10-16	Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
HU9601857D0 (en)	1996-08-28	New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
HK1015788A1 (en)	1999-10-22	Chiral methylphenyloxazolidinones
AU2102497A (en)	1997-09-22	Resolution of threo-methylphenidate
GR3024592T3 (en)	1997-12-31	Process for preparing and resolving 2-phenyl-3-aminopiperidine
CA2282279A1 (en)	1998-09-03	Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
UA41353C2 (uk)	2001-09-17	Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність
CA2296560A1 (en)	1999-01-28	Amino acid derivatives useful to treat stroke
ZA973156B (en)	1997-11-06	Process for the production of enantiomerically-pure azetidine-2-carboxylic acid.
IL122708A0 (en)	1998-08-16	Process for the production of enantiomerically-pure azetidine-2-carboxylic acid
IL128028A0 (en)	1999-11-30	Treatment of psychotic disorders
EP0804186A4 (de)	1998-04-22	Indolditerpen alkaloide
MY101747A (en)	1992-01-17	Dihydroorotic acids derivative, processes for preparing the same
MX9704704A (es)	1997-12-31	Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
PL352119A1 (en)	2003-07-28	Derivatives of aminotetraline for treatment of cardiovascular diseases
HUT77439A (hu)	1998-04-28	Új eljárás ranitidin előállítására
MX9604692A (es)	1998-04-30	Derivados de quinoxalina para el tratamiento de tinnitus.
JO2127B1 (en)	2000-05-21	How to prevent asthma
JO1720B1 (en)	1993-06-15	Heterocyclic derivatives
SI0906255T1 (en)	2001-12-31	Process for the production of enantiomerically-pure azetidine-2-carboxylic acid